Technology
Health
Biotechnology

Eidos Therapeutics

$36.32
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$2.81 (-7.18%) Today
-$0.01 (-0.03%) As of 4:21 PM EDT after-hours

Why Robinhood?

You can buy or sell EIDX and other stocks, options, ETFs, and crypto commission-free!

About EIDX

Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. Read More The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA.

Employees
24
Headquarters
San Francisco, California
Founded
2013
Market Cap
1.44B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
198.00K
High Today
$38.99
Low Today
$34.60
Open Price
$38.99
Volume
263.37K
52 Week High
$41.35
52 Week Low
$8.89

Collections

Technology
Health
Biotechnology
Therapy
2018 IPO
US
North America

EIDX News

BenzingaJun 26

BridgeBio Pharma IPO: What You Need To Know

171

EIDX Earnings

-$0.38
-$0.34
-$0.29
-$0.25
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.38 per share
Actual
Expected Aug 6, After Hours

More EIDX News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.